Tysabri price jumps
The price of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) upon relaunch in July will be 20.8% higher than when it was first approved in November 2004, according to information on Elan's website. Tysabri's new wholesale acquisition cost will be $2,184.62 per vial compared to $1,808 in 2004. FDA reapproved natalizumab June 5 with an extensive risk management program to prevent cases of progressive multifocal leukoencephalopathy. Biogen/Elan have attributed higher pricing to additional costs associated with administering the risk management plan as well as the inclusion of new efficacy data in labeling (1"The Pink Sheet" June 12, 2006, p. 8)...
You may also be interested in...
Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.